AA
RCKT icon

AlphaCentric Advisors’s Rocket Pharmaceuticals RCKT Stock Holding History

AlphaCentric Advisors’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-800
Closed -$44K – 220
2020
Q4 		$44K Buy
800
+350
+78% +$12.8K 0.02% 189
2020
Q3 		$10K Sell
450
-50
-10% -$1.23K ﹤0.01% 157
2020
Q2 		$10K Buy
+500
New +$9.02K 0.01% 135

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

AlphaCentric Advisors's RCKT Position: Q1 2021 in Review

AlphaCentric Advisors sold out of Rocket Pharmaceuticals (RCKT) in Q1 2021, closing a stake of 800 shares — an estimated $44K sold.

AlphaCentric Advisors first reported a position in RCKT in Q2 2020 and held it in 3 quarters. The position peaked at $44K in Q4 2020. 173 funds tracked by Wall St. Rank hold RCKT as of Q1 2021.

  • AlphaCentric Advisors reported no remaining Rocket Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • AlphaCentric Advisors sold 800 Rocket Pharmaceuticals shares in Q1 2021, an estimated $44K.
  • AlphaCentric Advisors first reported a position in Rocket Pharmaceuticals in Q2 2020 and held it in 3 quarters.
  • AlphaCentric Advisors's Rocket Pharmaceuticals position peaked at $44K in Q4 2020.
  • 173 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2021.

Based on AlphaCentric Advisors's 13F filing for Q1 2021, filed 9 Mar 2022.